Visus Therapeutics has revealed positive topline results from VIVID, the company’s Phase 2 study of three novel topical ophthalmic formulations under investigation for the treatment of presbyopia.
Nicox SA revealed positive post-hoc data from its Mississippi Phase 2b clinical trial, finding that once-daily dosed NCX 4251, fluticasone propionate ophthalmic suspension 0.1%, is beneficial in alleviating dry eye symptoms in a subgroup of patients.
Kiora Pharmaceuticals revealed topline data from its vehicle-controlled, randomized safety study of KIO-101 eye drops.
Nanodropper launched its "2022 Give the Gift of Vision" program, which aims to donate 1,000 Nanodropper adaptors to at-need patients in the United States and its international nonprofit partners.
Salvat Laboratories has submitted the NDA documentation for a new drug application to the FDA for approval of Clobetasol, the first ocular corticosteroid formulated in a nanoemulsion for inflammation and pain in patients undergoing eye surgery.
New study has paved the way for a long-lasting eye drop to treat corneal neovascularization (CoNV), a disease that affects over a million individuals worldwide every year.
Théa Pharma announced the availability of the iVIZIA line of over-the-counter (OTC) eye care products in the United States. The iVIZIA OTC product line includes lubricating eye drops, lubricating eye gel, and three options for daily hygiene of sensitive e